R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study

Haematologica

Volumn 93, Issue 12, 2008, Pages 1829-1836

  Martín, Alejandro ^a,r   Conde, Eulogio ^b   Arnan, Montserrat ^c   Canales, Miguel A ^d   Deben, Guillermo ^e   Sancho, Juan M ^f   Andreu, Rafael ^g   Salar, Antonio ^h   García Sanchez, Pedro ⁱ   Vázquez, Lourdes ^j   Nistal, Sara ^k   Requena, María José ^l   Donato, Eva M ^m   González, José A ⁿ   León, Ángel ^o   Ruiz, Concepción ^p   Grande, Carlos ^q   González Barca, Eva ^c   Caballero, María Dolores ^j  

^a Hospital Provincial de Zamora   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^l HOSPITAL SEVERO OCHOA   (Spain)

^m HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁿ HOSPITAL VIRGEN DEL PUERTO   (Spain)

^o HOSPITAL DE JEREZ   (Spain)

^p HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^q HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^r Complejo Hospitalario de Zamora ^*  (Spain)

more..

Author keywords

Diffuse large B cell lymphoma; R ESHAP; Rituximab; Salvage therapy

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; EMBOLISM; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS;

EID: 57349104217     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13440     Document Type: Article

References (26)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
2. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on high-dose Therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999;17:423-9.
3. Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, Vose J, et al. ASBMT Expert Panel: the role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001;7:308-31.
4. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996;92:880-9.
5. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-85.
6. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-22.
7. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76.
8. Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8:675-80.
9. Caballero MD, Amigo ML, Hernández JM, Vazquez L, del Cañizo C, Gonzalez M, et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann Hematol 1997;74:79-82.
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
11. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
12. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIMDHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537-43.
13. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-8.
14. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006;24:593-600.
15. Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of phase II study. Ann Oncol 2004;15:511-6.
16. Oztürk MA, Bariflta I, Altunda MK, Türker A, Yalçin S, Celik I, et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy 2002;48:252-8.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
18. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363-8.
19. Gisselbrecht C, Schmitz N, Mounier N, Ma D, Trneny M, Hagberg H, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007;110 Suppl:[abstract 517].
20. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
21. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005:329-34.
22. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007; 233-42.
23. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562-8.
24. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000;18:332-9.
25. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-96.
26. Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 2004;15:1504-9.